Ivermectin In Treatment of COVID 19 Patients

• Status: Recruiting
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ministry of Health and Population, Egypt
• Treatments: Hydroxychloroquine; Ivermectin

Criteria

Inclusion Criteria:

• Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

Exclusion Criteria:

• Contraindications for the drug: hypersensitivity.

• Any medications with possible drug interactions.

• Severe cases.

• Any malignant condition.

• Pregnant females.

• Breast feeding females.

• Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.